Developer docs
API playgroundTry for free, no card

Search company profiles

5AM Ventures

Full company profile

uuid00003bz

Namestring
5AM Ventures
Legal namestring
5AM Venture Management, LLC
Websiteurl
5amventures.com
Company typeenum
Private
Founded yearint
2002
Descriptiontext

5AM Ventures is a privately-held life science venture capital firm founded in 2002 that finances and builds next-generation therapeutics, drug delivery technologies, and life science instrument companies. The firm operates three distinct vehicles: the flagship 5AM Ventures fund (Series A-focused private therapeutics investing, currently in its seventh vintage at $450M); 5AM Opportunities, a public equities strategy investing in small and mid-cap public and later-stage private biotech (currently $300M in its second vintage); and the 4:59 Initiative, an internal incubator that partners alongside academics and entrepreneurs to generate proof-of-concept data that enables Series A financings. The firm is organized as 5AM Venture Management, LLC, a Delaware-domiciled registered investment adviser, and maintains offices in San Francisco, California and Boston, Massachusetts.

Short descriptiontext

5AM Ventures is a privately-held life science venture capital firm founded in 2002 that finances and builds early-stage therapeutics companies, operating $750M across a Series A-focused venture fund, a public/later-stage opportunities fund, and the 4:59 Initiative incubator.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSan Francisco, United States
HQ citystring
San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
venture capital funding, life sciences investment, biotech venture capital, early-stage therapeutics, healthcare venture capital
Industry3 codes
PRIMARYFSANAAAD
Sector-Focused Venture Capital (Vertical Specialists)
SECONDARYFSANACAB
Healthcare & Life Sciences Growth Equity
SECONDARYFSANAAAB
Early-Stage Venture Capital (Series A/B)
NAICS code2 codes
  • Funds, Trusts, and Other Financial Vehicles525
  • Other Investment Pools and Funds5259
SIC code1 code
  • Investment Advice6282
Product category
Venture Capital - Life Sciences
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Venture Capital Management Fees and Carried Interest
TypeLicensing Royalties
Description

5AM Ventures generates returns through management fees charged on committed capital across its funds (5AM Ventures VII at $450M and 5AM Opportunities II at $300M as of January 2025), and carried interest (performance fees) on successful exits of portfolio companies. Fund data as of January 1, 2025 shows $450M under management for the latest venture fund and $300M for the opportunities fund.

5amventures.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Operations, Marketing or Sales, Others
Pricing details1 tier
1Venture Capital Fund Investment (by institution/qualified investor)
ModelOtherBilling cadenceMulti-year contract
Notes

5AM Ventures VII ($450M) and 5AM Opportunities II ($300M) are private investment funds not publicly offered. Terms (management fees, carried interest, LP commitments) are not publicly disclosed.

5amventures.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 3 records shown
14:59 Initiative
Description

5AM's hands-on internal effort to discover, incubate, and fund breakthrough science, partnering alongside academics and entrepreneurs to establish proof-of-concept data for Series A financing.

5amventures.com
+2 more records
Core offering1 text field

5AM Ventures is a life science venture capital firm that finances and builds next-generation life sciences companies. The firm deploys capital through three strategies: the 5AM Ventures venture capital fund (Series A-focused private therapeutic companies), the 5AM Opportunities public equity strategy (small/mid-cap public and later-stage private biotech), and the 4:59 Initiative, an internal incubator that partners alongside academics and entrepreneurs to establish proof-of-concept data enabling Series A financing.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Over 90,000 patients enrolled across 450+ clinical trial sites by portfolio companies
+1 more record
Product overview1 text field

5AM Ventures is a life science venture capital firm offering two primary investment strategies: (1) 5AM Ventures, its core venture capital fund focused on early-stage private therapeutic companies with emphasis on Series A financing, and (2) 5AM Opportunities, its public equity strategy investing in small and mid-cap public and later-stage private biotech companies. Additionally, the firm operates the 4:59 Initiative, an internal incubation effort that partners with academics and entrepreneurs to develop proof-of-concept data for breakthrough science prior to Series A funding. The firm currently manages $450M from 5AM Ventures VII and $300M from 5AM Opportunities II.

Product and service3 records
15AM Ventures VII
CategoryVenture Capital Fund
Description

Venture capital fund for institutional and qualified investors that invests in private therapeutic companies, typically early-stage with emphasis on Series A financing. Currently investing $450M across biopharmaceuticals, drug delivery technologies, and life science instruments.

25AM Opportunities II
CategoryPublic Equity Fund
Description

Public equity strategy fund for institutional and qualified investors that invests in small and mid-cap public and later-stage private biotech and life science companies, complementing the venture capital strategy.

34:59 Initiative
CategoryCompany Incubation Program
Description

Internal incubator program for academics and entrepreneurs developing breakthrough science. Partners alongside founders to establish proof-of-concept data that enables Series A financing, often serving as an extension of the operating team.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Early-stage life sciences venture firm based in Boston that builds biotech companies from inception through Series A. Atlas Venture is one of the closest comparables to 5AM given similar size, sector focus, and company-formation approach.

TypeDirect peer
Description

Boston-based life sciences VC that focuses on company formation and building therapeutic platforms from inception. Closely comparable to 5AM's 4:59 Initiative model and Series A emphasis.

TypeDirect peer
Description

Large early-stage life sciences and technology venture firm that co-invests alongside 5AM in deals such as Prolynx and Mendra. ARCH is comparable as a sector-focused specialist with multi-fund platform and incubation capabilities.

TypeDirect peer
Description

Healthcare-dedicated investment firm across private equity, venture, and public equities. OrbiMed is a frequent co-investor with 5AM (Prolynx, Mendra) and operates a similar dual-strategy venture and public opportunities platform.

TypeDirect peer
Description

Cambridge-based life sciences company-formation firm that incubates and builds biotech platforms from inception. Highly comparable to 5AM's hands-on 4:59 Initiative incubation model.

TypeDirect peer
Description

Crossover healthcare investment manager with both private and public biotech exposure. RA Capital competes with 5AM Opportunities II in the public/small-cap biotech arena and participates in private crossover rounds.

TypeDirect peer
Description

Healthcare-focused venture firm investing across therapeutics, medical devices, and diagnostics. Comparable as a sector specialist of similar scale with public/private strategies.

TypeDirect peer
Description

Technology and life sciences venture firm that co-invested in Mendra alongside 5AM. Lux's growing biotech practice overlaps with 5AM's therapeutic focus.

TypeDirect peer
Description

Technology and biotech venture firm that co-led Mendra's Series A alongside 5AM. 8VC's increasing life sciences practice makes it a comparable newer entrant in healthcare VC.

TypeBroad incumbent
Description

Large multi-stage venture firm with a dedicated healthcare practice. Comparable to 5AM as a generalist with significant life sciences exposure, though NEA's broader sector mandate makes it a broad incumbent rather than a specialist.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment220 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

5AM Ventures

Venture Capital - Life Sciences5amventures.com

5AM Ventures is a privately-held life science venture capital firm founded in 2002 that finances and builds early-stage therapeutics companies, operating $750M across a Series A-focused venture fund, a public/later-stage opportunities fund, and the 4:59 Initiative incubator.

What 5AM Ventures does

5AM Ventures is a privately-held life science venture capital firm founded in 2002 that finances and builds next-generation therapeutics, drug delivery technologies, and life science instrument companies. The firm operates three distinct vehicles: the flagship 5AM Ventures fund (Series A-focused private therapeutics investing, currently in its seventh vintage at $450M); 5AM Opportunities, a public equities strategy investing in small and mid-cap public and later-stage private biotech (currently $300M in its second vintage); and the 4:59 Initiative, an internal incubator that partners alongside academics and entrepreneurs to generate proof-of-concept data that enables Series A financings. The firm is organized as 5AM Venture Management, LLC, a Delaware-domiciled registered investment adviser, and maintains offices in San Francisco, California and Boston, Massachusetts.

5AM Ventures firmographics

Firmographics
Name
5AM Ventures
Legal name
5AM Venture Management, LLC
Website
https://5amventures.com
Company type
Private
Founded year
2002
Operating status
Operating
Headcount range
11–50 employees
Short description
5AM Ventures is a privately-held life science venture capital firm founded in 2002 that finances and builds early-stage therapeutics companies, operating $750M across a Series A-focused venture fund, a public/later-stage opportunities fund, and the 4:59 Initiative incubator.
Ownership category
akta.pro rank

5AM Ventures industry classification

Industry
Product category
Venture Capital - Life Sciences
NAICS
Funds, Trusts, and Other Financial Vehicles (525), Other Investment Pools and Funds (5259)
SIC
Investment Advice (6282)
akta.pro industry
PRIMARYFSANAAAD
Sector-Focused Venture Capital (Vertical Specialists)
SECONDARYFSANACAB
Healthcare & Life Sciences Growth Equity
SECONDARYFSANAAAB
Early-Stage Venture Capital (Series A/B)

Keywords

  • Venture capital funding
  • Life sciences investment
  • Biotech venture capital
  • Early-stage therapeutics
  • Healthcare venture capital

Where 5AM Ventures is headquartered

Location

Headquarters

HQ city
San Francisco
HQ country
United States
HQ region
North America

Offices2 records

Markets served

5AM Ventures business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Venture Capital Management Fees and Carried Interest: 5AM Ventures generates returns through management fees charged on committed capital across its funds (5AM Ventures VII at $450M and 5AM Opportunities II at $300M as of January 2025), and carried interest (performance fees) on successful exits of portfolio companies. Fund data as of January 1, 2025 shows $450M under management for the latest venture fund and $300M for the opportunities fund.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractVenture Capital Fund Investment (by institution/qualified investor)

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

5AM Ventures product offering

Product offering

Core offering

5AM Ventures is a life science venture capital firm that finances and builds next-generation life sciences companies. The firm deploys capital through three strategies: the 5AM Ventures venture capital fund (Series A-focused private therapeutic companies), the 5AM Opportunities public equity strategy (small/mid-cap public and later-stage private biotech), and the 4:59 Initiative, an internal incubator that partners alongside academics and entrepreneurs to establish proof-of-concept data enabling Series A financing.

Product overview

5AM Ventures is a life science venture capital firm offering two primary investment strategies: (1) 5AM Ventures, its core venture capital fund focused on early-stage private therapeutic companies with emphasis on Series A financing, and (2) 5AM Opportunities, its public equity strategy investing in small and mid-cap public and later-stage private biotech companies. Additionally, the firm operates the 4:59 Initiative, an internal incubation effort that partners with academics and entrepreneurs to develop proof-of-concept data for breakthrough science prior to Series A funding. The firm currently manages $450M from 5AM Ventures VII and $300M from 5AM Opportunities II.

Differentiator

Problem solved

Functional benefit

Brands

  • 4:59 Initiative: 5AM's hands-on internal effort to discover, incubate, and fund breakthrough science, partnering alongside academics and entrepreneurs to establish proof-of-concept data for Series A financing.
  • 5AM Ventures VII
  • 5AM Opportunities II

Products and services

  • 5AM Ventures VII Venture capital fund for institutional and qualified investors that invests in private therapeutic companies, typically early-stage with emphasis on Series A financing. Currently investing $450M across biopharmaceuticals, drug delivery technologies, and life science instruments.
  • 5AM Opportunities II Public equity strategy fund for institutional and qualified investors that invests in small and mid-cap public and later-stage private biotech and life science companies, complementing the venture capital strategy.
  • 4:59 Initiative Internal incubator program for academics and entrepreneurs developing breakthrough science. Partners alongside founders to establish proof-of-concept data that enables Series A financing, often serving as an extension of the operating team.

Quantifiable outcome

  • Over 90,000 patients enrolled across 450+ clinical trial sites by portfolio companies
  • +1 more outcomes

Companies that use 5AM Ventures

Customer profile

Segments1 record

Ideal customer profiles2 records

5AM Ventures technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

5AM Ventures partnerships and signals

Strategic signal

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

5AM Ventures competitors and assessment

Company assessment

Direct peers

  • Atlas Venture: Early-stage life sciences venture firm based in Boston that builds biotech companies from inception through Series A. Atlas Venture is one of the closest comparables to 5AM given similar size, sector focus, and company-formation approach.
  • Third Rock Ventures: Boston-based life sciences VC that focuses on company formation and building therapeutic platforms from inception. Closely comparable to 5AM's 4:59 Initiative model and Series A emphasis.
  • ARCH Venture Partners: Large early-stage life sciences and technology venture firm that co-invests alongside 5AM in deals such as Prolynx and Mendra. ARCH is comparable as a sector-focused specialist with multi-fund platform and incubation capabilities.
  • OrbiMed: Healthcare-dedicated investment firm across private equity, venture, and public equities. OrbiMed is a frequent co-investor with 5AM (Prolynx, Mendra) and operates a similar dual-strategy venture and public opportunities platform.
  • Flagship Pioneering: Cambridge-based life sciences company-formation firm that incubates and builds biotech platforms from inception. Highly comparable to 5AM's hands-on 4:59 Initiative incubation model.
  • RA Capital Management: Crossover healthcare investment manager with both private and public biotech exposure. RA Capital competes with 5AM Opportunities II in the public/small-cap biotech arena and participates in private crossover rounds.
  • Frazier Life Sciences: Healthcare-focused venture firm investing across therapeutics, medical devices, and diagnostics. Comparable as a sector specialist of similar scale with public/private strategies.
  • Lux Capital: Technology and life sciences venture firm that co-invested in Mendra alongside 5AM. Lux's growing biotech practice overlaps with 5AM's therapeutic focus.
  • 8VC: Technology and biotech venture firm that co-led Mendra's Series A alongside 5AM. 8VC's increasing life sciences practice makes it a comparable newer entrant in healthcare VC.

Broad incumbents

  • New Enterprise Associates (NEA): Large multi-stage venture firm with a dedicated healthcare practice. Comparable to 5AM as a generalist with significant life sciences exposure, though NEA's broader sector mandate makes it a broad incumbent rather than a specialist.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

5AM Ventures social profiles

Digital presence

5AM Ventures financial estimates

Financial estimate

Revenue estimate

Valuation estimate

5AM Ventures leadership team

Management profile

Number of profiles

Profiles10 records

5AM Ventures funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

5AM Ventures M&A and investment

M&A and investment

M&A

Investments220 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about 5AM Ventures

What does 5AM Ventures do?

5AM Ventures is a life science venture capital firm that finances and builds next-generation life sciences companies. The firm deploys capital through three strategies: the 5AM Ventures venture capital fund (Series A-focused private therapeutic companies), the 5AM Opportunities public equity strategy (small/mid-cap public and later-stage private biotech), and the 4:59 Initiative, an internal incubator that partners alongside academics and entrepreneurs to establish proof-of-concept data enabling Series A financing.

Is 5AM Ventures a public or private company?

5AM Ventures is a private company. It is classified as management employee owned and is currently operating.

When was 5AM Ventures founded?

5AM Ventures was founded in 2002. It employs 11 to 50 people.

Where is 5AM Ventures based?

5AM Ventures is headquartered in San Francisco, United States, in the North America region.

How does 5AM Ventures make money?

One revenue line is on record: venture Capital Management Fees and Carried Interest.

Who are 5AM Ventures's main competitors?

Direct peers on record are Atlas Venture, Third Rock Ventures, ARCH Venture Partners, OrbiMed, Flagship Pioneering, RA Capital Management, Frazier Life Sciences, Lux Capital and 8VC. New Enterprise Associates (NEA) is listed as a broad incumbent.

Does 5AM Ventures have an API?

No public API is recorded for 5AM Ventures.

What industry is 5AM Ventures in?

5AM Ventures's product category is Venture Capital - Life Sciences. Its primary akta.pro industry code is FSANAAAD, Sector-Focused Venture Capital (Vertical Specialists), with a secondary code of FSANACAB, Healthcare & Life Sciences Growth Equity. Its NAICS code is 525 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Defense World5AM Venture Management LLC Acquires Shares of 1,029,298 Tyra Biosciences, Inc. $TYRA5AM Venture Management LLC bought 1,029,298 shares of Tyra Biosciences in the second quarter, valued at about $32.9 million, according to its SEC filing. The stake represents 11.4% of the firm's portfolio and 1.72% of Tyra, making it the second largest position. Institutional investors hold 84.14% of the stock.Defense World5AM Venture Management LLC Makes New Investment in ALX Oncology Holdings Inc. $ALXO5AM Venture Management LLC disclosed in its latest SEC filing that it bought 3,057,325 shares of ALX Oncology Holdings in the second quarter, valued at about $6.33 million, representing 2.2% of its portfolio and its 14th largest position. Institutional investors hold 97.97% of the stock, and the company reported quarterly EPS of -$0.13, beating the -$0.14 consensus estimate.Defense World5AM Venture Management LLC Makes New $27.58 Billion Investment in Pharvaris N.V. $PHVS5AM Venture Management LLC disclosed in its SEC filing that it bought 797,600 shares of Pharvaris N.V. in the second quarter, valued at about $27.58 million, for a 1.22% stake, making the stock its fourth largest position. JPMorgan increased its holdings by 30.6% to 3,342 shares, while insiders Anna Nijdam and Johannes Gerardus Chri Schikan sold 121,325 shares in the last 90 days.BusinessCloud$125m financing to see Macclesfield’s Redx list on NasdaqRedx Pharma, a Macclesfield-based biotech, agreed a $125m financing deal to list on Nasdaq as Fibrx Therapeutics. The deal includes a $36m Series A led by Abingworth and a $68m private placement, with Sky Bioscience acquiring Redx. The combined company will fund operations through 2029 and key clinical milestones, including RXC008 Phase 2 data expected in H2 2028.Investing.com5am Ventures V, L.P. sells $431,829 of Entrada Therapeutics stock By Investing.com5am Ventures V, L.P. sold $431,829 of Entrada Therapeutics stock through multiple transactions in early August 2026. The company's stock experienced a 32% decline year-to-date and trades significantly below its 52-week high, despite analyst views suggesting it remains undervalued. Entrada Therapeutics announced an approval to proceed with a higher dose in a clinical trial, indicating ongoing progress in its research programs.Investing.com5am Ventures V sells $807,027 of Entrada Therapeutics stock By Investing.com5AM Ventures V, L.P., a 10% owner and director of Entrada Therapeutics, Inc., disposed of company stock totaling $807,027 over two days (July 30-31, 2026) at weighted average prices of $6.93 and $6.85 per share. The sales occurred as Entrada Therapeutics stock surged 24.5% over the past week, trading at $7.26 above the disposal prices, leaving 5AM Ventures V with 2,846,592 shares directly held. Separately, Entrada Therapeutics announced that an independent Data Monitoring Committee cleared a higher dose (10 mg/kg) for its ELEVATE-45-201 Duchenne Muscular Dystrophy study, and the company is scheduled to release topline Phase 1/2 results for ENTR-601-44 within the coming days.Investing.com5am Ventures V sells $807,027 of Entrada Therapeutics stock By Investing.com5AM Ventures V, a 10% owner and director of Entrada Therapeutics, disposed of company common stock totaling $807,027 over two days (July 30-31, 2026), selling 116,474 shares at prices ranging from $6.85 to $6.93 per share. Following the transactions, 5AM Ventures V retains direct ownership of 2,846,592 shares while the stock trades at $7.26, above the sale prices, after surging 24.5% over the past week. Separately, Entrada Therapeutics received approval from an independent Data Monitoring Committee to proceed with a higher dose in its ELEVATE-45-201 study for Duchenne Muscular Dystrophy and is scheduled to report topline results from its Phase 1/2 ELEVATE-44-201 study on ENTR-601-44.BioSpaceCAMP4 Therapeutics Secures Australian Regulatory Clearance to Initiate First-in-Human Clinical Trial of CMP-002 in Patients With SYNGAP1-Related DisorderCAMP4 Therapeutics received TGA and HREC clearance to start its Phase 1/2 trial of CMP-002 for SYNGAP1-related disorder. The clearance triggers eligibility for up to $50 million in gross proceeds from a second private placement closing within five business days.ProlynxincPress ReleaseProlynx, a biotechnology company based in Emeryville, California, announced the closing of a $70 million Series A financing co-led by 5AM Ventures, OrbiMed, and Monograph Capital, along with the appointment of Chris Boulton as Chief Executive Officer. The capital will advance the company's proprietary pipeline of ultra-long-acting incretin and non-incretin therapies for obesity and metabolic conditions, designed to enable monthly and quarterly dosing regimens. Founder Daniel Santi transitions to Chief Technical and Scientific Officer to focus on research, with Boulton bringing over 25 years of global pharmaceutical leadership experience in metabolic and obesity therapies from prior roles at Amgen, Sanofi, and AstraZeneca.GlobeNewswireJoshua Grass, John Kelly, and Lauren Daniel Join 5AM Ventures5AM Ventures announced the addition of Joshua Grass as Venture Partner, John Kelly as CFO and COO, and Lauren Daniel as Chief Compliance Officer and Deputy General Counsel. The firm, which has raised over $2.2 billion and invested in 140+ companies, aims to strengthen its investment capabilities and governance.